Corindus Announces First Commercial Installation of CorPath GRX System Outside of U.S.


WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc.(NYSE American: CVRS), a leading developer of precision vascular robotics, announced today the first commercial installation of a CorPath GRX System outside of the United States. The system was purchased by the Apex Heart Institute in Ahmedabad, India, a state of the art cardiology center. Corindus will partner with Apex Heart Institute to develop a Global Center of Excellence to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

The hospital’s first complete robotic procedure was performed via left dorsal transradial access by Tejas Patel, M.D. Dr. Patel is Chairman and Chief Interventional Cardiologist at the Apex Heart Institute and a global key opinion leader and pioneer of the transradial access technique, training over 5,000 physicians on his techniques over the course of his career. Procedures performed via transradial access have shown significant benefits for patients including reduced incidence of major bleeding and vascular complications and increased patient satisfaction.

"After completing the initial cases with CorPath GRX, I and my partner Dr. Sanjay Shah are very impressed by the capabilities of the system in complex procedures and the level of precision we are able to deliver," stated Dr. Patel. "Robotics is an important component of the future of interventional cardiology at Apex Heart Institute. We look forward to pioneering this technology in India and around the world."

Mark Toland, President and Chief Executive Officer of Corindus, stated "We are pleased that Apex Heart Institute has launched the first robotic program in India, successfully performing eleven PCI procedures during its first three days of use. India represents a new and developing market area for Corindus, and we are looking forward to working with Dr. Patel and the Apex Heart Institute as we introduce our precision vascular robotics to this area."

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit, and follow @CorindusInc.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.